Alexion to Pick Goldman to Advise on Roche Offer?

July 30 (Bloomberg) -- Alexion Pharmaceuticals, the drugmaker whose blood-disease treatment is among the world’s most expensive medicines, engaged Goldman Sachs as an adviser as it prepares for a possible takeover offer from Roche, said people with knowledge of the matter. Cristina Alesci reports on Bloomberg Television's "Money Moves." (Source: Bloomberg)

UBS's Ermotti Says Environment In 2Q 'Very Challenging'
01:39 - UBS Group AG said first-quarter profit fell 64 percent, missing analyst estimates, as all divisions reported a drop in earnings. Net income fell to 707 million Swiss francs ($741 million) from 1.98 billion francs a year earlier, the Zurich-based bank said on Tuesday. That fell short of the 735 million-franc average estimate of five analysts in a Bloomberg survey. UBS CEO Sergio Ermotti told Bloomberg Television’s Guy Johnson that the issues the bank highlighted in previous quarters aren’t disappearing.
  • BNP 1Q Net Profit Rises on Lower Loan-Loss Provisions
  • Why We're Cautious on Saudi Banks: Arqaam's Meijer
  • RBA Cuts Benchmark Interest Rate to 1.75%